Semaglutide

Overview

Semaglutide is a 31-amino acid modified peptide with a molecular weight of approximately 4,114 Da, developed by Novo Nordisk as a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It is FDA-approved under the brand names Ozempic (subcutaneous injection for type 2 diabetes), Wegovy (subcutaneous injection for chronic weight management), and Rybelsus (oral tablet for type 2 diabetes).

Structurally, semaglutide shares 94% homology with native human GLP-1 but incorporates three critical modifications: substitution of alanine with alpha-aminoisobutyric acid (Aib) at position 8 to confer resistance to dipeptidyl peptidase-4 (DPP-4) degradation, attachment of a C-18 fatty diacid chain via a linker to lysine at position 26 to enable albumin binding, and substitution of lysine with arginine at position 34 to prevent fatty acid attachment at that site. These modifications extend the plasma half-life from approximately 2 minutes (native GLP-1) to approximately 7 days, enabling once-weekly dosing.

Mechanism of Action

Semaglutide activates GLP-1 receptors expressed throughout multiple organ systems, producing coordinated metabolic effects:

• Pancreas: Enhanced glucose-dependent insulin secretion from beta cells and suppressed glucagon release from alpha cells, improving glycemic control without significant hypoglycemia risk
• Brain: Activation of GLP-1 receptors in hypothalamic satiety centers reduces appetite and food intake, with emerging evidence of effects on reward-related eating behavior
• Gastrointestinal tract: Delayed gastric emptying reduces postprandial glucose excursions and contributes to satiety signaling
• Cardiovascular system: Direct and indirect cardioprotective effects including reduced inflammation, improved endothelial function, and decreased atherosclerotic plaque progression

The albumin-binding C-18 fatty acid chain creates a circulating depot, with semaglutide existing predominantly in the albumin-bound state, providing sustained receptor activation throughout the dosing interval.

Research Evidence

Semaglutide has the most extensive clinical evidence base of any peptide in this class, supported by multiple large-scale randomized controlled trials.

The SUSTAIN program (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) comprised multiple Phase III trials establishing semaglutide's efficacy in type 2 diabetes. SUSTAIN-6 (PMID: 27633186) was a cardiovascular outcomes trial demonstrating a 26% reduction in major adverse cardiovascular events (MACE) compared with placebo in patients with type 2 diabetes at high cardiovascular risk (HR 0.74; 95% CI 0.58-0.95).

The SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity; PMID: 37952131), published in the New England Journal of Medicine, enrolled 17,604 adults with overweight or obesity and established cardiovascular disease but without diabetes. Semaglutide 2.4 mg weekly reduced the primary MACE endpoint by 20% (HR 0.80; 95% CI 0.72-0.90; P < 0.001), with events occurring in 6.5% of the semaglutide group versus 8.0% in placebo. Notably, further analysis indicated the cardioprotective effects were largely independent of baseline adiposity and weight loss magnitude.

The STEP trials (Semaglutide Treatment Effect in People with Obesity) demonstrated mean body weight reductions of 14.9% to 17.4% with semaglutide 2.4 mg weekly in individuals with obesity, with or without type 2 diabetes.

Potential Applications

• Type 2 diabetes mellitus: FDA-approved for glycemic control (Ozempic, Rybelsus)
• Chronic weight management: FDA-approved for adults with obesity or overweight with at least one weight-related comorbidity (Wegovy)
• Cardiovascular risk reduction: Demonstrated MACE reduction in both diabetic and non-diabetic populations
• Non-alcoholic steatohepatitis (NASH): Active Phase III clinical trials investigating hepatic effects
• Chronic kidney disease: Emerging evidence of renoprotective effects in diabetic nephropathy
• Heart failure with preserved ejection fraction: Clinical trials investigating functional and symptomatic improvements

Safety Considerations

The most common adverse effects are gastrointestinal: nausea (reported in 15-44% of patients depending on dose and trial), vomiting, diarrhea, and constipation. These effects are typically dose-dependent, most prominent during dose escalation, and tend to diminish over time. Gradual dose titration protocols are employed to mitigate GI tolerability issues.

Serious but less frequent safety signals include pancreatitis (reported rarely in clinical trials and post-marketing surveillance), potential risk of medullary thyroid carcinoma (based on rodent studies showing thyroid C-cell tumors, leading to a boxed warning; relevance to humans remains uncertain), and gallbladder-related events including cholelithiasis.

Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2). Potential drug interactions include enhanced hypoglycemia risk when combined with sulfonylureas or insulin. Long-term safety data beyond 2-3 years of continuous use remain limited for the higher doses used in weight management.